Search Within

Gopakumar Vasudeva Iyer

  1. "Genitourinary Oncology Service"
Formats
  1. Meeting Abstract (202)
  2. Journal Article (118)
  3. Review (11)
  4. Book Section (5)
  5. Editorial (3)
  6. Correspondence (2)
  7. Research Letter (1)
Groups
  1. Department of Medicine (342)
  2. Genitourinary Oncology Service (342)
  3. Solid Tumor Oncology Division (342)
  4. Department of Pathology and Laboratory Medicine (214)
  5. GSK Faculty (194)
  6. Human Oncology and Pathogenesis Program (191)

More Groups

People
  1. Hikmat Al-Ahmadie (182)
  2. David Solit (181)
  3. Jonathan Rosenberg (169)
  4. Dean Bajorin (160)
  5. Bernard Bochner (129)
  6. Michael Berger (102)

More People

Years
  1. 2025 (14)
  2. 2024 (41)
  3. 2023 (30)
  4. 2022 (33)
  5. 2021 (34)
  6. 2020 (22)

More Years

Publications
  1. Journal of Clinical Oncology (117)
  2. Laboratory Investigation (27)
  3. Modern Pathology (20)
  4. Cancer Research (17)
  5. Clinical Cancer Research (14)
  6. Annals of Oncology (13)

More Publications

Publishers
  1. American Society of Clinical Oncology (125)
  2. Nature Publishing Group (43)
  3. American Association for Cancer Research (34)
  4. Elsevier Inc. (33)
  5. Nature Research (20)
  6. Oxford University Press (15)

More Publishers

Results (342)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Immune checkpoint blockade response in mucinous tubular and spindle cell carcinoma
    Journal Article

    Makker, S.; Shah, N. J.; Carlo, M. I.; Kuo, F.; Hakimi, A. A.; Chen, Y. B.; Iyer, G.; Kotecha, R. R.
    Current Oncology (2025)

    Fulltext@MSK | Save
  • Molecular heterogeneity and immune infiltration drive clinical outcomes in upper tract urothelial carcinoma
    Journal Article

    Kim, K.; Alam, S. M.; Kuo, F.; Chen, Z.; Yip, W.; Katims, A. B.; Chu, C.; Lenis, A. T.; Hu, W.; Gokturk Ozcan, G.; more...
    European Urology (2025)

    Fulltext@MSK | Save
  • Loss of KMT2C or KMT2D primes urothelium for tumorigenesis and redistributes KMT2A-menin to bivalent promoters
    Journal Article

    Wang, N.; Pachai, M. R.; Li, D.; Lee, C. J.; Warda, S.; Khudoynazarova, M. N.; Cho, W. H.; Xie, G.; Shah, S. R.; Yao, L.; more...
    Nature Genetics (2025)

    Fulltext@MSK | Save
  • Use of dupilumab to manage a grade 3 cutaneous adverse effect from enfortumab vedotin/pembrolizumab treatment in a patient with metastatic urothelial carcinoma
    Journal Article

    Gillis, M. C.; Weir, V. R.; Lezcano, C.; Iyer, G.; Gordon, A.
    JAAD Case Reports (2025)

    Fulltext@MSK | Save
  • Clinical outcomes of patients with metastatic urothelial carcinoma (mUC) discontinuing enfortumab vedotin (EV) monotherapy (mono) without disease progression
    Meeting Abstract

    Sternschuss, M.; Whiting, K.; Teo, M. Y.; Bajorin, D.; Kotecha, R.; Laccetti, A. L.; Xiao, H.; Feld, E.; McHugh, D. J.; Keegan, N.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • EV-302: Exploratory analysis of nectin-4 expression and response to 1L enfortumab vedotin (EV) + pembrolizumab (P) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC)
    Meeting Abstract

    Powles, T. B.; van der Heijden, M. S.; Gupta, S.; Perez Valderrama, B.; Galsky, M. D.; Bedke, J.; Kikuchi, E.; Hoffman-Censits, J.; Maroto Rey, J. P.; Vulsteke, C.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • UPLIFT (ENGOT-ov67/GOG-3048): Results from the phase II trial of upifitamab rilsodotin, a NaPi2b-directed dolaflexin antibody-drug conjugate, in platinum-resistant ovarian cancer
    Meeting Abstract

    Richardson, D.; Iyer, G.; Schmid, A.; Palma, N.; Navarro, W.; Ahnert, J. R.
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • NEXUS-01, a phase 1 study of LY4052031, an antibody-drug conjugate targeting nectin-4 in participants with advanced or metastatic urothelial carcinoma or other solid tumors (trial in progress)
    Meeting Abstract

    Baldini, C.; Patnaik, A.; Lakhani, N.; Call, J.; Galsky, M.; Garmezy, B.; Wei, A.; Carter, L.; Powles, T.; Siefker-Radtke, A.; more...
    European Journal of Cancer (2024)

    Fulltext@MSK | Save
  • Preliminary safety and anti-tumor activity of TYRA-300, a highly selective FGFR3 inhibitor, in participants with advanced solid tumors with activating FGFR3 mutations/fusions (SURF301)
    Meeting Abstract

    Tran, B.; Boni, A.; Hansen, A.; Boni, V.; Mantia, C.; Yu, E.; Weickhardt, A.; Robert, M.; Gupta, S.; Necchi, A.; more...
    European Journal of Cancer (2024)

    Fulltext@MSK | Save
  • TYRA-300, an oral, FGFR3-selective inhibitor: Preliminary pharmacokinetic and pharmacodynamic analysis from SURF301, the multicenter open-label phase 1/2 study of TYRA-300 in advanced urothelial carcinoma and other solid tumors with activating FGFR3 alterations
    Meeting Abstract

    Loriot, Y.; Zhang, A.; Hansen, A.; Mantia, C.; Boni, V.; Weickhardt, A.; Yu, E. Y.; Robert, M.; Iyer, G.; Murtha, A.; more...
    European Journal of Cancer (2024)

    Fulltext@MSK | Save